Anavex Encouraged by New Sigma-1 Receptor Study That May Explain Therapeutic Efficacy of ANAVEX 2-73 for Alzheimer’s Disease October 22, 2013
Anavex to Present at Upcoming Rodman & Renshaw Annual Global Investment Conference in New York September 3, 2013
Anavex to Present at Upcoming Rodman & Renshaw Annual Global Investment Conference in New York September 3, 2013
Anavex Raises $2.6-Million in Private Placement and Conversion of Liabilities, Enters Into $10-Million Financing Commitment and Appoints CEO July 8, 2013
ANAVEX 2-73 Restores Mitochondrial Functionality, Blocks Cell Death and Oxidative Stress, Preventing Onset of Alzheimer’s Disease March 12, 2013
Mitochondrial protection in mouse hippocampus against Aß25-35 toxicity is induced by the novel tetrahydrofuran derivative ANAVEX2-73, a mixed σ1 receptor and cholinergic agonist. March 6, 2013
Anavex Retains Novak Druce Connolly Bove & Quigg to Maximize Value of Intellectual Property Portfolio February 4, 2013
Amyloid toxicity induced by oligomeric Aβ25-35 injection is enhanced after pharmacologic or genetic invalidation of the σ1 chaperone protein January 11, 2013
